Private Capital Management Inc. Has $714,000 Stake in Celgene Corporation (CELG)
Private Capital Management Inc. maintained its position in shares of Celgene Corporation (NASDAQ:CELG) during the second quarter, Holdings Channel reports. The firm owned 5,500 shares of the biopharmaceutical company’s stock at the end of the second quarter. Private Capital Management Inc.’s holdings in Celgene Corporation were worth $714,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of CELG. Dubuque Bank & Trust Co. raised its stake in Celgene Corporation by 5.9% in the second quarter. Dubuque Bank & Trust Co. now owns 49,367 shares of the biopharmaceutical company’s stock worth $6,411,000 after buying an additional 2,740 shares in the last quarter. BB&T Corp increased its stake in shares of Celgene Corporation by 21.2% in the second quarter. BB&T Corp now owns 23,956 shares of the biopharmaceutical company’s stock worth $3,111,000 after buying an additional 4,194 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Celgene Corporation by 1.7% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 42,626 shares of the biopharmaceutical company’s stock worth $5,536,000 after buying an additional 714 shares during the last quarter. Whittier Trust Co. increased its stake in shares of Celgene Corporation by 1.9% in the second quarter. Whittier Trust Co. now owns 114,213 shares of the biopharmaceutical company’s stock worth $14,833,000 after buying an additional 2,163 shares during the last quarter. Finally, US Bancorp DE increased its stake in shares of Celgene Corporation by 6.7% in the second quarter. US Bancorp DE now owns 763,301 shares of the biopharmaceutical company’s stock worth $99,130,000 after buying an additional 48,085 shares during the last quarter. Institutional investors and hedge funds own 78.34% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) traded up 1.39% on Monday, reaching $132.42. The company had a trading volume of 985,789 shares. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00. The firm has a market capitalization of $103.60 billion, a PE ratio of 41.01 and a beta of 1.89. The company has a 50-day moving average price of $134.14 and a 200-day moving average price of $124.30.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.44 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/private-capital-management-inc-has-714000-stake-in-celgene-corporation-celg/1487370.html.
A number of brokerages have recently issued reports on CELG. Cantor Fitzgerald set a $159.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, April 27th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a report on Monday, July 31st. BMO Capital Markets reissued an “outperform” rating and issued a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a report on Friday, July 28th. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Tuesday, June 6th. Finally, BidaskClub raised shares of Celgene Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $147.00.
In other news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock worth $31,377,042 over the last quarter. 0.95% of the stock is currently owned by corporate insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.